[Cutaneous lesions due to inhibition of epidermal growth factor receptor]

Area of Science:

• Oncology
• Dermatology
• Pharmacology

Background:

• Malignant tumors are increasingly treated with molecularly targeted therapies, including biologics.
• Epidermal growth factor receptor (EGFR) inhibitors are a class of biologics used in cancer therapy.
• Cutaneous adverse events are a prominent side effect profile of EGFR inhibitors.

Purpose of the Study:

• To review the spectrum of cutaneous lesions associated with EGFR inhibitors.
• To explore the relationship between the severity of skin reactions and the efficacy of EGFR inhibitors.

Main Methods:

• Literature review of studies investigating EGFR inhibitors and their adverse drug reactions.
• Analysis of reported cutaneous side effects, including acneiform eruptions, xerosis, and nail changes.
• Correlation analysis between the incidence and severity of dermatological reactions and treatment outcomes.

Main Results:

• Acneiform eruptions are the most frequent skin reaction, followed by xerosis, eczema, and nail/hair changes.
• The intensity of cutaneous manifestations varies significantly among patients.
• A positive correlation was observed between the severity of skin reactions and the therapeutic effectiveness of EGFR inhibitors.

Conclusions:

• Cutaneous lesions are a common and significant adverse effect of EGFR inhibitor therapy.
• The observed correlation between skin toxicity and treatment efficacy suggests potential for personalized dose adjustments.
• Monitoring and managing dermatological side effects are crucial for maintaining therapeutic continuity and optimizing patient outcomes.